Todos os estudos
RecrutamentoFASE2INTERVENCIONISTA

MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab

Chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) are slow-growing cancers affecting white blood cells. Many people respond well to their first treatment, but the condition often returns over time. This study, called MAVRiC, is exploring whether a combination of two targeted drugs—acalabrutinib and venetoclax—can help adults whose leukaemia has come back. It is for people who previously had a similar targeted treatment combination that worked well for at least two years after finishing it. Both drugs work by blocking specific proteins that cancer cells need to survive and grow. Instead of taking treatment indefinitely, participants receive these medicines for a fixed period. Researchers want to see how well the cancer responds and monitor any side effects. Taking part lasts for up to five years, including regular health checks and long-term monitoring.

Em resumo

Status
Recrutamento
Fase
FASE2
Patrocinador
AstraZeneca
Meta de inscrição
80
Iniciar
04 Jun 2026
Conclusão estimada
23 Mar 2033

Sobre o que é este estudo?

Chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) are closely related conditions that affect white blood cells called lymphocytes. In these conditions, the body makes too many abnormal white blood cells that do not work properly. While modern targeted treatments can keep the condition under control for years, it is common for the cancer to eventually return.

The MAVRiC study is testing a treatment option for adults whose CLL or SLL has come back. It focuses specifically on people who previously received a combination of targeted medicines that kept the disease in check for at least two years after finishing treatment. Researchers want to find out whether using two targeted drugs, acalabrutinib and venetoclax, can successfully control the condition a second time.

Acalabrutinib and venetoclax attack cancer cells in different ways. Acalabrutinib blocks signals that tell leukaemia cells to multiply, while venetoclax blocks a protein that stops abnormal cells from dying. By taking both together, doctors hope to clear the cancer cells more effectively. Participants receive the drugs for a set period rather than continuously, giving them a planned break from treatment once the course is complete.

Finding safe and reliable second-line treatments is an important goal for doctors caring for people with CLL and SLL. The results of this study will help show whether retreatment with this drug combination is effective, how long the benefits last, and how well patients tolerate the medication.

Pontos principais

  • Tests a combination of two targeted drugs: acalabrutinib and venetoclax.
  • Open to adults with CLL or SLL that has returned after successful initial treatment.
  • Treatment is given for a set amount of time rather than continuously.
  • Total study participation lasts up to five years, including follow-up checks.
  • Taking part is voluntary, and you can leave the study at any time.

Quem pode ser elegível?

This study is open to adults aged 18 and over who have been diagnosed with CLL or SLL that has returned and now requires further medical treatment. To take part, you must have had only one previous course of treatment using a combination of targeted drugs (known as a BTK inhibitor and a BCL2 inhibitor). That initial treatment must have kept your leukaemia well-controlled for at least two years after it finished.

You will need to have routine blood and genetic tests before starting, which help the research team understand the specific features of your leukaemia. You also need to be reasonably active and able to look after yourself in daily life.

You may not be eligible if you have serious heart conditions, severe liver disease, or a history of bleeding disorders. You also cannot take part if you take certain blood-thinning medicines like warfarin, have had major surgery within the last month, or have active infections such as hepatitis or HIV.

Este estudo pode ser adequado para você?

Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.

  1. I am aged 18 or older.
  2. I have been diagnosed with CLL or SLL that has returned and needs treatment.
  3. My previous treatment was a targeted drug combination that kept my condition stable for at least two years.
  4. I do not have severe heart disease, severe liver disease, or bleeding problems.
  5. I am not currently taking warfarin or other similar blood thinners.
Responda a todas as perguntas para ver o seu resultado.

O que envolve a participação?

If you join the MAVRiC study, your total involvement will last for up to five years. It begins with a screening phase where the medical team runs health checks, scans, and blood tests to make sure the trial is safe for you. During the treatment period, you will take acalabrutinib and venetoclax as prescribed for a fixed duration. You will attend regular hospital appointments for check-ups, blood tests, and scans to see how your body and leukaemia are responding. After finishing the medication, you will enter a follow-up phase where the team monitors your health and keeps track of your recovery over the remaining years.

Riscos e benefícios potenciais

Taking part may help shrink your leukaemia and keep it under control without the need for traditional chemotherapy, although there is no guarantee that the treatment will work for everyone. Both acalabrutinib and venetoclax can cause side effects, including an increased risk of infections, low blood counts, bruising, or an upset stomach. Your healthcare team will watch you very closely and provide care to manage any side effects. Joining the study is completely voluntary, and you are free to leave at any time without it affecting your usual NHS medical care.

Locations (47)

  • Site de Pesquisa
    Código postal verificado
    Boston, Estados Unidos· Recrutamento
  • Site de Pesquisa
    Código postal verificado
    Charlotte, Estados Unidos· Retirado
  • Site de Pesquisa
    Código postal verificado
    Charlotte, Estados Unidos· Recrutamento
  • Site de Pesquisa
    Código postal verificado
    Durham, Estados Unidos· Recrutamento
  • Site de Pesquisa
    Código postal verificado
    Winston-Salem, Estados Unidos· Recrutamento
  • Site de Pesquisa
    Código postal verificado
    Horn, Austria· Recrutamento
  • Site de Pesquisa
    Código postal verificado
    Goiânia, Brazil· Ainda não recrutando
  • Site de Pesquisa
    Código postal verificado
    Porto Alegre, Brazil· Ainda não recrutando
  • Site de Pesquisa
    Código postal verificado
    Porto Alegre, Brazil· Ainda não recrutando
  • Site de Pesquisa
    Código postal verificado
    São Paulo, Brazil· Ainda não recrutando
  • Site de Pesquisa
    Código postal verificado
    São Paulo, Brazil· Ainda não recrutando
  • Site de Pesquisa
    Código postal verificado
    Brno, Tchéquia· Ainda não recrutando

Perguntas frequentes

Qual é o principal objetivo deste estudo?

The study tests whether giving two targeted medicines together can safely and effectively control CLL or SLL after it has returned following earlier treatment.

How are the study medicines taken?

Both acalabrutinib and venetoclax are oral medicines taken by mouth, usually as tablets or capsules, for a set period.

Is this trial using chemotherapy?

No. These are targeted therapies designed to block specific proteins inside cancer cells, rather than traditional chemotherapy drugs.

Do I have to pay for the treatment?

No. The trial medicines and any study-related tests or appointments are provided at no cost to you.

What happens if my cancer gets worse during the trial?

Your doctors will monitor your health closely. If the trial treatment stops working, you will be taken off the study drugs and offered alternative care options.

Como saber mais

Centro de Informações de Estudos Clínicos da AstraZeneca

Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.

Interessado em participar?

Registre seu interesse

Compartilhe seus detalhes e a equipe de pesquisa para "MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL…" entrará em contato com você se você for elegível. Sempre fale com seu médico antes de concordar em participar.

Discussão

Discussão da comunidade

Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.